All In Biotech

Drug Trial Radar · NCT06823258

Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Feb 28, 2025

Primary completion

Jul 31, 2025

Study completion Jul 31, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will be conducted in subjects with moderate Hepatic Impairment, mild hepatic Impairment and normal hepatic function. The study will be conducted in two stages. Based on the research results of moderate hepatic Impairment and matched control subjects with normal hepatic function, the sponsor will make a comprehensive analysis to decide whether it is necessary to conduct a study on the mild hepatic Impairment and matched control subjects with normal hepatic function

Conditions

  • NSCLC (advanced Non-small Cell Lung Cancer)

Interventions

  • HS-10365Drug

    HS-10365 administered orally once at D1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak plasma concentration (Cmax) of HS-10365Time frame: From the first dose (Day 0) up to Day 6
  2. Pharmacokinetic parameters AUC0-t of HS-10365Time frame: From the first dose (Day 0) up to Day 6
  3. Pharmacokinetic parameters AUC0-∞ of HS-10365Time frame: From the first dose (Day 0) up to Day 6

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.